Login to Your Account

Medivir's Simeprevir Aces Three Phase III HCV Trials

By Cormac Sheridan
Staff Writer

Friday, December 21, 2012
Top-line data from three Phase III trials of simeprevir (TMC435) in patients with hepatitis C virus (HCV) genotype 1 infection appear to confirm what Medivir AB has always maintained – that it has a potentially best-in-class protease inhibitor on its hands.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription